Saniona completes SAN2465 tox, CMC studies, targets IND filing by end-October 2026
Bitget2026/09/24 06:03- Saniona completed toxicology and CMC work for SAN2465, clearing the package needed to support an IND filing.
- IND submission to the FDA is targeted by end-October 2026, setting up first-in-human dosing plans.
- Planned Phase 1 trial targets safety, tolerability, pharmacokinetics in healthy volunteers, with biomarker readouts to inform dose selection.
- SAN2465 targets GABA-A α5 receptors for major depressive disorder, aiming for ketamine-like rapid onset with an oral profile.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
